Navigation Links
Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Date:10/25/2009

on or suicidal ideation. Lorcaserin's selective activation of an important receptor associated with reduced food intake avoids these liabilities. We believe the data presented at Obesity 2009 will support our new drug application and we look forward to working with the FDA to provide physicians and patients with lorcaserin."

Previously announced BLOOM data demonstrate that lorcaserin helped patients achieve clinically meaningful weight loss and maintenance of weight loss over two years of treatment. In the per protocol population, nearly two-thirds (66.4%) of lorcaserin patients lost at least 5% of their weight, compared to 32.1% of patients on placebo, and over one-third (36.2%) of lorcaserin patients lost at least 10% of their weight, compared to 13.6% for placebo. The average weight loss in this population was 17.9 pounds in the lorcaserin group, compared to 7.4 pounds in the placebo group. Using ITT-LOCF analysis, 67.9% of Year 1 lorcaserin responders maintained at least 5% weight loss during Year 2, compared to 50.3% for those patients re-randomized from lorcaserin treatment in Year 1 to placebo in Year 2.

Lorcaserin improved patients' lipid profiles, insulin resistance and markers of inflammation, with the greatest improvements observed in those with abnormal values at the start of the study. Treatment with lorcaserin was well tolerated, resulting in very few adverse events with greater frequency than the placebo group, and did not increase cardiac valvulopathy. Lorcaserin's tolerability profile eliminates the need for titration; patients began treatment on the full dose and achieved rapid weight loss. Almost one-third of lorcaserin patients lost at least 5% of their body weight by Week 8.

Patient Disposition

BLOOM evaluated 3,182 patients with an average BMI of 36.2 and baseline weight of 220 pounds. The Week 52 completion rate was higher for patients on lorcaserin (55.4%) compared to patients on placebo (45
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. UCLA/RAND study shows that many children of HIV-positive parents are not in their custody
3. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
4. Nutrition model stresses positive experience of eating
5. Ultrasound plus mammography finds more cancers, but increases false positives
6. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
7. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
8. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
9. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
10. A low prevalence of H pylori in HIV-positive patients
11. Drug Company-Funded Asthma Drug Studies More Positive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 03, 2014 Recently, Top 10 ... companies and announced that JustHost ( http://www.justhost.com/track/seohosts ) ... webmasters. , “The hosting suppliers we recommend are ... competitors on hosting features, uptime and server speed ... Best SEO Hosting says. “We believe that BlueHost ...
(Date:9/2/2014)... The exciting information sessions and AMTC ... Carey Lewis and Bob Wiley. The team of ... have the desire to illuminate entertainment with the light ... be invited to join the Bridge Training Program ... Saturday, Sept. 6, Charlotte Convention Center, 501 South College ...
(Date:9/2/2014)... Washington, DC (PRWEB) September 02, 2014 TCG, ... named by Inc. 5000 as one of the fastest-growing companies ... the eighth time total. TCG was previously recognized in 2013, ... 2001. , TCG’s revenue has grown 86% from 2010 to ... of the fastest growing businesses in America - up 635 ...
(Date:9/2/2014)... 02, 2014 Friendship Village of ... “This creates a contemporary marketing presence and ... its parent organization, Friendship Senior Options,” said Stephen ... Options. “By changing the logo, we are making ... to seniors and their families.” , Friendship Village ...
(Date:9/2/2014)... September 02, 2014 Cloud Medical Doctor ... “Cloud Based” Medical Practice Business Operations solutions and Billing ... Digital Cyber Security solutions for all industries announced today ... the trading floor of the CME in Chicago by ... stated that we are very proud of the recognition ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3
... the recent economic downturn, natural health degree ... still experiencing a wellness boom, as holistic ... the Internet,s top natural health career site ... training, chiropractic, nutrition, Reiki and reflexology career ...
... Upsher-Smith announces the launch of www.prenexa.com , a web site ... with more plant-based DHA (docosahexaenoic acid) than any other prenatal vitamin. ... ... Upsher-Smith announces the launch of prenexa.com, a web site devoted to ...
... from the Dutch Health Insurance System model, according to an ... of the Journal of Health Politics, Policy and Law ... at The University of Texas School of Public Health at ... coverage in the Netherlands and its possible lessons for the ...
... prevention and treatment for people living with HIV/AIDS. , ... ... annual World AIDS Day , global health activists gathered for ... today that nearly 6,000 people from 163 countries signed a petition ...
... SAN FRANCISCO, Dec. 8 Quantros, a leading ... healthcare industry, today,announced that the Agency for Healthcare ... Quantros Patient Safety Center as a Patient Safety,Organization ... . The Quantros Patient Safety Center,is a new ...
... iron from the heart in beta-thalassemia patients with mild to severe ... a subgroup analysis of 341 patients with myelodysplastic syndromes (MDS), Exjade ... -These results are part of the largest prospective trial ... transfusion-dependent anemias , , EAST HANOVER, ...
Cached Medicine News:Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Upsher-Smith Laboratories Launches Prenexa.com to Support Prenatal Nutrition and Health 2Health News:Upsher-Smith Laboratories Launches Prenexa.com to Support Prenatal Nutrition and Health 3Health News:UT public health policy expert says US can learn from Dutch universal health-care coverage 2Health News:Thousands Sign Petition for Action on HIV/AIDS and Malaria 2Health News:Thousands Sign Petition for Action on HIV/AIDS and Malaria 3Health News:Thousands Sign Petition for Action on HIV/AIDS and Malaria 4Health News:Quantros Patient Safety Center Receives Certification as a Patient Safety Organization (PSO) 2Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 2Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 3Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 4Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 5Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 6Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 7Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 8Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 9
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... 2, 2014 , ... provide insight into treatment and outcomes of patients ... --   Data from nearly 12,500 ... the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic ... for atrial fibrillation (AF) patients remain sub-optimal despite ...
(Date:9/2/2014)... -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... at the Morgan Stanley Global Healthcare Conference in ... September 9, 2014 , Presentation time: 5:15 p.m. ET ... of this presentation will be available at http://ir.avanir.com . ... Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... is the principal hormone responsible for the control ... the b-cells of the islets of Langerhans as ... C-peptide and insulin. Both are secreted in ... mature insulin molecule is comprised of two polypeptide ...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: